In addition to PRP solutions, Kealor provides a comprehensive range of high-quality medical and aesthetic products, including spinal needles, bone marrow needles, blunt needle cannulas, peptides, dermal fillers, and NAD+ medical aesthetic products
And a study published in January 2025 suggested that popular GLP-1 medications approved for weight loss, diabetes and heart disease may have untapped potential to reduce the risks of substance abuse disorders, psychosis, infections and some kinds of cancer and dementia
In a study published in JAMA Network Open in January 2025, which included more than 125,000 patients, nearly 65 percent of those taking GLP1s for reasons other than Type 2 diabetes discontinued them within one year
Conversely, patients with type 2 diabetes are at an increased risk of developing a thyroid disorder, especially women